Fast vs. Slow Switching from Stimulants to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

被引:3
作者
Cardo, Esther [1 ]
Porsdal, Vibeke
Quail, Deborah [2 ]
Fuentes, Joaquin [3 ]
Steer, Christopher [4 ]
Montoya, Alonso [5 ]
Anand, Ernie [6 ]
Escobar, Rodrigo [7 ]
机构
[1] Son Llatzer Univ Balearic Isl, Neuropediat Hosp, Univ Inst Res Healthcare Sci, Dept Neuropediat, E-07198 Palma De Mallorca, Spain
[2] Lilly UK, European Stat, Windlesham, Surrey, England
[3] Policlin Gipuzkoa, San Sebastian 20009, Spain
[4] Victoria Hosp, Dept Paediat, Kirkcaldy, Fife, Scotland
[5] Lilly Labs Spain, Dept Med, Alcobendas, Spain
[6] Neurosci Med Affairs EU, Windlesham, Surrey, England
[7] Lilly Res Labs Japan, Med Sci, Neurosci Prod, Chuo Ku, Kobe, Hyogo, Japan
关键词
DEFICIT HYPERACTIVITY DISORDER; BLOOD-PRESSURE; METHYLPHENIDATE; AMPHETAMINE; EFFICACY; VALIDITY;
D O I
10.1089/cap.2012.0027
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To compare fast versus slow switching from stimulants to atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods: This was a randomized, controlled, open-label study in 6-16-year-old ADHD patients, previously treated with stimulants and cross-titrated (fast switch, over 2 weeks, or slow switch, over 10 weeks) to ATX because of unsatisfactory response and/or adverse events. Study duration was 14 weeks with an ATX standard target dose of 1.2 mg/kg/day. Primary measure was the change from baseline in the investigator-rated ADHD-Rating Scale (ADHD-RS) at weeks 2 and 10. Secondary measures included Global Impression of Perceived Difficulties (GIPD) and Child Health and Illness Profile-Child Edition (CHIP-CE). Results: The majority of the 111 patients were male (83.8%, n = 93) and mean (SD) age was 11.5 (2.38) years. Mean baseline ADHD-RS total score was 36.0 in the fast and 38.0 in the slow group. Adjusted mean change after 2 weeks was -8.1 (-10.1; -6.1) in the fast and -8.0 (-9.9; -6.0) in the slow group (p = 0.927), and after 10 weeks -15.0 (-17.4; -12.6) and -14.3 (-16.7; -12.0), respectively, (p = 0.692). GIPD scores did not show differences between groups. Significant differences at week 10 were found in the CHIP-CE achievement domain favoring slow (p = 0.036) and the comfort domain favoring fast cross-titration (p = 0.030). No significant differences were found for adverse events, and differences for systolic blood pressure (BP) and weight were not considered clinically relevant. Conclusions: ADHD-RS and GIPD scores improved in both switching groups. No clinically relevant differences between fast and slow switching from stimulants to ATX were found.
引用
收藏
页码:252 / 261
页数:10
相关论文
共 23 条
[11]   Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder [J].
Montoya, Alonso ;
Hervas, Amaia ;
Cardo, Esther ;
Artigas, Josep ;
Mardomingo, Maria J. ;
Alda, Jose A. ;
Gastaminza, Xavier ;
Garcia-Polavieja, Maria J. ;
Gilaberte, Inmaculada ;
Escobar, Rodrigo .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) :2745-2754
[12]   Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants [J].
Posner, Kelly ;
Oquendo, Maria A. ;
Gould, Madelyn ;
Stanley, Barbara ;
Davies, Mark .
AMERICAN JOURNAL OF PSYCHIATRY, 2007, 164 (07) :1035-1043
[13]   Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: Clinical approaches and review of current available evidence [J].
Prasad S. ;
Steer C. .
Pediatric Drugs, 2008, 10 (1) :39-47
[14]   Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder - A preliminary tolerability and efficacy study [J].
Quintana, Humberto ;
Cherlin, Edward A. ;
Duesenberg, David A. ;
Bangs, Mark E. ;
Ramsey, Janet L. ;
Feldman, Peter D. ;
Allen, Albert J. ;
Kelsey, Douglas K. .
CLINICAL THERAPEUTICS, 2007, 29 (06) :1168-1177
[15]   Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition [J].
Riley, Anne W. ;
Coghill, David ;
Forrest, Christopher B. ;
Lorenzo, Maria J. ;
Ralston, Stephen J. ;
Spiel, Georg .
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2006, 15 (Suppl 1) :63-71
[16]   REPRODUCIBILITY AND PREDICTIVE VALUES OF ROUTINE BLOOD-PRESSURE MEASUREMENTS IN CHILDREN - COMPARISON WITH ADULT VALUES AND IMPLICATIONS FOR SCREENING-CHILDREN FOR ELEVATED BLOOD-PRESSURE [J].
ROSNER, B ;
COOK, NR ;
EVANS, DA ;
KEOUGH, ME ;
TAYLOR, JO ;
POLK, BF ;
HENNEKENS, CH .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1987, 126 (06) :1115-1125
[17]   Determination of blood pressure percentiles in normal-weight children: Some methodological issues [J].
Rosner, B. ;
Cook, N. ;
Portman, R. ;
Daniels, S. ;
Falkner, B. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (06) :653-666
[18]   Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials [J].
Schacht, Alexander ;
Escobar, Rodrigo ;
Wagner, Thomas ;
Wehmeier, Peter M. .
ADHD-ATTENTION DEFICIT AND HYPERACTIVITY DISORDERS, 2011, 3 (04) :335-349
[19]   Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle [J].
Spencer, T ;
Biederman, J ;
Wilens, T ;
Harding, M ;
ODonnell, BAD ;
Griffin, S .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1996, 35 (04) :409-432
[20]   Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: Reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day [J].
Wehmeier P.M. ;
Schacht A. ;
Dittmann R.W. ;
Döpfner M. .
Child and Adolescent Psychiatry and Mental Health, 2 (1)